RecruitingPhase 1NCT05714072
Rare condition
Essential thrombocythemia
48
studies recruiting now
as of 7 Sept 2026
341
studies registered in total
as of 7 Sept 2026
24
countries with a recruiting site
as of 7 Sept 2026
3 Jun 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT07469891
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
RecruitingPhase 2NCT06661915
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RecruitingPhase 3NCT07357727
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
RecruitingPhase 3NCT07623200
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 48 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Essential thrombocythemia study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Essential thrombocythemia
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (TET2, JAK2, MPL, CALR, SH2B3, TP53).
Treatments being studied
5 approved treatments and 14 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: AnagrelideApproved: Ruxolitinib (Jakavi)Approved: Anagrelide Hydrochloride (Agrelin)Approved: Momelotinib Dihydrochloride (Ojjaara)Approved: Peginterferon Alfa-2a (Pegasys)
Phase 3Hydroxyurea (Droxia)
Phase 3Ruxolitinib Phosphate (Jakafi)
Phase 3Bomedemstat
Phase 3Aspirin (8-hour bayer)
Phase 3Ropeginterferon Alfa-2b (Besremi)
Phase 2Tipifarnib
Phase 2Lestaurtinib
Phase 2Vorinostat (Zolinza)
+ 6 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).